Silence Therapeutics plc (SLN, SLNCF) – SEC staff letter
2026-01-09 · Re: Form 10-K fo the fiscal year ended December 31, 2024 · Accession 0000000000-26-000315 · Review completed (no further comments)
January 9, 2026 Rhonda Hellums Chief Financial Officer Silence Therapeutics plc 12 Hammersmith Road London, W14 8TH United Kingdom Re: Silence Therapeutics plc Form 10-K fo the fiscal year ended December 31, 2024 File No. 001-39487 Dear Rhonda Hellums: We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Sincerely, Division of Corporation Finance Office of Life Sciences
Full letter on EDGAR → · Filing index · All Silence Therapeutics plc (SLN, SLNCF) correspondence
Templates & resources
- AICPA & CIMA – SEC reporting resources (AICPA & CIMA · Professional body · Free / member)
- BDO Accounting, Reporting & Compliance Hub (ARCH) (BDO · Firm guide · Free)
- Deloitte DART – Roadmap Series (Deloitte · Firm guide · Free)
- Deloitte Roadmap: SEC Comment Letter Considerations (Deloitte · Firm guide · Free)
- KPMG Financial Reporting View (KPMG · Firm guide · Free)
- PwC Viewpoint (PwC · Firm guide · Free / paid)
- RSM Financial Reporting Resource Center (RSM · Firm guide · Free)
- SEC – EDGAR Full Text Search (SEC · Regulator · Free)